PMID- 24279470
OWN - NLM
STAT- MEDLINE
DCOM- 20141201
LR  - 20221207
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 16
IP  - 4
DP  - 2014 Apr
TI  - The association of serum vascular endothelial growth factor and ferritin in 
      diabetic microvascular disease.
PG  - 224-34
LID - 10.1089/dia.2013.0181 [doi]
AB  - BACKGROUND: Vascular endothelial growth factor (VEGF) is involved in the 
      pathogenesis of diabetic microvascular disease. Most diabetes patients have 
      higher serum levels of ferritin that may participate in diabetic vascular 
      complications through high oxidative stress induced by iron. However, the 
      mechanistic link between ferritin and VEGF is obscure. The study investigated the 
      association of VEGF and ferritin in patients with diabetic microvascular disease. 
      PATIENTS AND METHODS: Sixty patients with type 2 diabetes mellitus (T2DM) and 26 
      healthy individuals were selected in this study. Serum ferritin, VEGF, 
      hematological parameters, and clinical data were assessed in this cohort. The 
      Spearman rank method was used to evaluate the associations among them. RESULTS: 
      Serum levels of VEGF and ferritin were significantly higher in diabetes patients 
      compared with the controls; levels of both were elevated with development of the 
      disease. There were positive correlations between VEGF and glucose levels and 
      between VEGF and ferritin in diabetes groups, especially in patients with 
      diabetic retinopathy. Positive correlations were also found between VEGF level 
      and the parameters of age, hemoglobin, and albumin in patients with diabetes 
      hypertension. CONCLUSIONS: Our data suggest that high ferritin levels in T2DM are 
      closely related to the development of diabetic vascular complications through 
      interaction with VEGF.
FAU - Guo, Li
AU  - Guo L
AD  - Department of Hematology Laboratory, First Affiliated Hospital of Shantou 
      University Medical College , Shantou, Guangdong, China .
FAU - Jiang, Fang
AU  - Jiang F
FAU - Tang, Yue-Ting
AU  - Tang YT
FAU - Si, Meng-Ya
AU  - Si MY
FAU - Jiao, Xiao-Yang
AU  - Jiao XY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131126
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9007-73-2 (Ferritins)
SB  - IM
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/*metabolism/physiopathology
MH  - Diabetic Angiopathies/*metabolism/physiopathology
MH  - Disease Progression
MH  - Female
MH  - Ferritins/*metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hyperglycemia/*metabolism/physiopathology
MH  - Hypertension/metabolism
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
MH  - Male
MH  - Microcirculation
MH  - Middle Aged
MH  - Vascular Endothelial Growth Factor A/*metabolism
PMC - PMC3952528
EDAT- 2013/11/28 06:00
MHDA- 2014/12/15 06:00
PMCR- 2015/04/01
CRDT- 2013/11/28 06:00
PHST- 2013/11/28 06:00 [entrez]
PHST- 2013/11/28 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - 10.1089/dia.2013.0181 [pii]
AID - 10.1089/dia.2013.0181 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2014 Apr;16(4):224-34. doi: 10.1089/dia.2013.0181. Epub 
      2013 Nov 26.